Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY23 results · Apr–Jun 2022
Glenmark Pharmaceuticals reported revenue from operations of ₹2,777.29 crore (down 6.3% from Q1 FY22) and net profit of ₹211.11 crore (down 31.1% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,777.29 | 2,964.89 | −6.3% | 3,019.15 | −8.0% |
| Other income | 183.16 | 58.65 | +212.3% | 107.20 | +70.9% |
| Total income | 2,960.44 | 3,023.54 | −2.1% | 3,126.35 | −5.3% |
| Profit before tax | 408.01 | 443.55 | −8.0% | 269.69 | +51.3% |
| Net profit for the period | 211.11 | 306.53 | −31.1% | 172.57 | +22.3% |
| Attributable to shareholders of the company | 192.53 | 399.13 | −51.8% | 155.59 | +23.7% |
| EPS, basic (₹) | 6.82 | 10.86 | −37.2% | 5.51 | +23.8% |
| Net margin (%) | 7.6 | 10.3 | 5.7 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,911.93 | 2,142.12 | −10.7% | 1,785.54 | +7.1% |
| Other income | 346.52 | 138.21 | +150.7% | 178.98 | +93.6% |
| Total income | 2,258.45 | 2,280.32 | −1.0% | 1,964.53 | +15.0% |
| Profit before tax | 695.55 | 598.40 | +16.2% | 224.78 | +209.4% |
| Net profit for the period | 492.58 | 489.42 | +0.6% | 205.60 | +139.6% |
| EPS, basic (₹) | 17.46 | 17.34 | +0.7% | 7.29 | +139.5% |
| Net margin (%) | 25.8 | 22.8 | 11.5 |
Consolidated
- Filed with BSE
- 12 Aug 2022, 12:15 IST
- Board meeting
- 10 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2022, 12:15 IST
- Board meeting
- 10 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE